aTyr Pharma, Inc. (ATYR)
ATYRNASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$6.21
0.0000 (0.00%) today
Regular session, Nov 13, 1:41 PM ET
- Market cap
- $15.83m
- P/E
- –
- EPS, last 4 quarters
- $-21.83
- Dividend yield
- –
- Day range
- $5.95 to $6.53
- 52-week range
- $4.07 to $44.40
- Average volume
- –
- Previous close
- $6.21
Analysts
5 coveringHold0 buy, 5 hold, 0 sell
Targets a year out average $5.00, -19.5% from here
Earnings
next estimate $-6.91Next report
Dec 2025
+22.2%
Mar 2026
+31.3%
Jun 2026
+26.7%
Sep 2026
-68.9%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$14.80m | -$11.44m | -$10.88m | -$18.79m |
| Net income | -$13.96m | -$10.79m | -$10.31m | -$18.26m |
News
8 latest- aTyr Pharma Consensus Price Target Increased by 3,900.04% to $115.60Fintel · Nov 2, 2026
- ATYR Stock In Focus After FDA Alignment On Efzofitimod Phase 3 RTTNews · Sep 24, 2026
- ATyr Provides Tentative FDA Timeline For Phase 3 Efzofitimod In Lung Disease RTTNews · Sep 2, 2026
- 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More RTTNews · Sep 1, 2026
- Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals RTTNews · Aug 15, 2026
- ATyr Pharma Q2 Net Loss Narrows; Cuts Workforce By 60% To Advance Efzofitimod Into Phase 3 RTTNews · Aug 10, 2026
- Freedom Broker Upgrades aTyr Pharma (ATYR)Fintel · May 20, 2026
- Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal RTTNews · May 15, 2026
The company
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- atyrpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.